And let's not forget Psylocybin in addition to the excitement around IHL - 42X and IHL - 675A.
As a reminder. From Psychedelic Stock Watch......
"As all investors in psychedelic drug stocks already know, Canada-based MindMed Inc (US:MNMD / CAN:MMED) recently uplisted to the NASDAQ. Not surprisingly, this had a major impact on the stock." The share price immediately more-than-doubled on news of an IPO trading date.Trading volume (in early sessions) is roughly 10X pre-NASDAQ volume.
That’s a pretty big impact. But gaining a premier exchange listing (such as the NASDAQ) means even more than that..........Much more efficient capital-raising. Much more investment capital available.
A recent addition to the higher echelons is CYBIN, a biotech in the Psylocybin space getting conditional approval to list on the NYSE.
"A tier 1 listing in the U.S. can open up avenues to new and potential institutional buying, increased retail buying, and help increase the overall visibility of the company,” Cybin CEO Doug Drysdale told Benzinga. Market Cap - $600m CAD.
